时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, many patients eventually relapse and progress to castration-resistant prostate cancer (CRPC), and once metastatic disease develops, treatment options become limited and outcomes remain poor [–].；However, the molecular mechanisms that drive disease progression are still not fully defined, highlighting the need for novel diagnostic markers and therapeutic targets [–].；Accumulating evidence implicates KHSRP in tumorigenesis across multiple cancers; however, its effects appear modulated by tumor type and molecular background, with both pro-tumor and anti-tumor behaviors reported across different settings [].
方法
Gene expression profiles and corresponding clinical information of PCa patients were obtained from The Cancer Genome Atlas prostate adenocarcinoma cohort (TCGA-PRAD; ).；Gene expression values were log2-transformed when appropriate before statistical analysis.；KHSRP expression between tumor and normal tissues was compared using TCGA-PRAD and GTEx data and validated in GEO cohorts.；For survival analyses, patients were divided into high- and low-KHSRP expression groups according to the median KHSRP expression level in each cohort.
核心结论
Bioinformatic analysis showed that KHSRP expression was significantly upregulated in PCa tissues compared with normal prostate tissues in the unpaired analysis (Fig.；Further analysis revealed that higher KHSRP expression was significantly associated with more aggressive clinicopathological features, including advanced pathological T stage, higher Gleason score, and increased PSA level (Fig.；Patients with DSS events exhibited significantly higher KHSRP expression than those without DSS events (Fig. ‖ 结论：These findings indicate that KHSRP plays an important role in PCa progression and may serve as a promising therapeutic target.
局限
Interestingly, KHSRP may also exert anti-metastatic effects in certain settings by enhancing the maturation of miR-23a in non-small cell lung cancer and miR-192-5p in mammary epithelial cells, thereby limiting EMT and cell migration [, ].；Despite the strengths of this study, several limitations should be acknowledged.；First, although our data support an oncogenic role of KHSRP in PCa and identify DUSP6 as a key downstream effector, the precise binding sites through which KHSRP regulates DUSP6 remain to be defined and should be validated in future studies using dual-luciferase reporter assays and mutational analyses.
对本项目的价值
★☆☆☆☆ 相关范围内，作为背景与横向对照收录。
全文来源
PMC JATS 全文（正文 37,242 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：The RNA-binding protein KHSRP drives prostate cancer progression through a DUSP6 dependent axis.
- 期刊与标识：Biol Direct · PMID 42947190 · DOI 10.1186/s13062-026-00894-1
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。